Literature DB >> 29663615

Erythrodermic psoriasis and secukinumab: Our clinical experience.

Almudena Mateu-Puchades1, Sergio Santos-Alarcón1, Antonio Martorell-Calatayud2, Conrad Pujol-Marco3, Jose-Luis Sánchez-Carazo4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29663615     DOI： 10.1111/dth.12607

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  3 in total

Review 1.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Secukinumab in Erythrodermic Psoriasis: Real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites.

Authors:  Maitreyee Panda; Chinmoy Raj; Anil K Panda; Ipsita Debata
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

3.  Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08       Impact factor: 6.166
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.